within Pharmacolibrary.Drugs.ATC.J;

model J07BX06
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J07BX06</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Enterovirus 71 vaccines are inactivated vaccines developed to prevent infection by enterovirus 71 (EV71), a major cause of hand, foot, and mouth disease (HFMD), particularly in children. Several inactivated vaccines have been developed and approved in China, primarily for pediatric use.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic (PK) data directly reported in published literature, as vaccines are typically evaluated by immunogenicity and safety rather than absorption, distribution, metabolism, and excretion pharmacokinetic parameters.</p><h4>References</h4><ol><li><p>Zhu, Z, et al., &amp; Wang, H (2016). Transcutaneous immunization via rapidly dissolvable microneedles protects against hand-foot-and-mouth disease caused by enterovirus 71. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 243 291–302. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2016.10.019\">10.1016/j.jconrel.2016.10.019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27793685/\">https://pubmed.ncbi.nlm.nih.gov/27793685</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J07BX06;
